Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ambroxol + guaifenesin + levosalbutamol
- Development stage
- Unknown
- Lead developer
- Bengal Chemicals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AMOTUS-LS is a combination pharmaceutical product marketed by Bengal Biopharma, typically formulated as a syrup for the treatment of productive cough associated with bronchospasm. It contains three active ingredients: ambroxol, guaifenesin, and levosalbutamol (also known as levalbuterol). Ambroxol is a mucolytic agent that thins and loosens thick mucus (phlegm), making it easier to cough out. Guaifenesin is an expectorant that increases the volume of airway secretions to facilitate their removal. Levosalbutamol is a selective beta-2 adrenergic receptor agonist that acts as a bronchodilator, relaxing the smooth muscles in the airways to improve airflow. This combination is commonly used in the management of conditions such as bronchitis, bronchial asthma, and chronic obstructive pulmonary disease (COPD) where mucus clearance and airway obstruction are clinical concerns.
- Brand names
- AMOTUS-LS
- Other names
- ambroxol + guaifenesin + levalbuterol
02
Targets
ADRB2 (β2)
Beyond the preview
Go deeper on ambroxol + guaifenesin + levosalbutamol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ambroxol + guaifenesin + levosalbutamol.